Abou-Alfa GK - Search Results

1

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, Quinn DI, Braña I, Moreno V, Borad M, Loi S, Spanggaard I, Park H, Ford JM, Arnedos M, Stemmer SM, de la Fouchardiere C, Fountzilas C, Zhang J, DiPrimeo D, Savin C, Duygu Selcuklu S, Berger MF, Eli LD, Meric-Bernstam F, Jhaveri K, Solit DB, Abou-Alfa GK. Harding JJ, et al. Nat Commun. 2023 Feb 6;14(1):630. doi: 10.1038/s41467-023-36399-y. Nat Commun. 2023. PMID: 36746967 Free PMC article.

2

Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers.

Huitzil-Melendez FD, O'Reilly EM, Duffy A, Abou-Alfa GK. Huitzil-Melendez FD, et al. Surg Oncol Clin N Am. 2009 Apr;18(2):361-79, x. doi: 10.1016/j.soc.2008.12.006. Surg Oncol Clin N Am. 2009. PMID: 19306817 Review.

3

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.

Lee JK, Capanu M, O'Reilly EM, Ma J, Chou JF, Shia J, Katz SS, Gansukh B, Reidy-Lagunes D, Segal NH, Yu KH, Chung KY, Saltz LB, Abou-Alfa GK. Lee JK, et al. Br J Cancer. 2013 Aug 20;109(4):915-9. doi: 10.1038/bjc.2013.432. Epub 2013 Jul 30. Br J Cancer. 2013. PMID: 23900219 Free PMC article. Clinical Trial.

4

Treating advanced hepatocellular carcinoma: How to get out of first gear.

Harding JJ, Abou-Alfa GK. Harding JJ, et al. Cancer. 2014 Oct 15;120(20):3122-30. doi: 10.1002/cncr.28850. Epub 2014 Jun 4. Cancer. 2014. PMID: 24898783 Free article. Review.

5

Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?

Harding JJ, Abou-Alfa GK. Harding JJ, et al. Hepatobiliary Surg Nutr. 2014 Aug;3(4):168-71. doi: 10.3978/j.issn.2304-3881.2014.07.03. Hepatobiliary Surg Nutr. 2014. PMID: 25202691 Free PMC article.

6

From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma.

Abu-Zeinah G, Owen D, Prieto-Granada C, Rekhtman N, Klimstra D, Gupta D, Harding J, Abou-Alfa GK. Abu-Zeinah G, et al. Gastrointest Cancer Res. 2014 May;7(3-4):103-7. Gastrointest Cancer Res. 2014. PMID: 25276264 Free PMC article. No abstract available.

7

Systemic therapy for hepatocellular carcinoma.

Harding JJ, Abou-Alfa GK. Harding JJ, et al. Chin Clin Oncol. 2013 Dec;2(4):37. doi: 10.3978/j.issn.2304-3865.2013.07.06. Chin Clin Oncol. 2013. PMID: 25841916 Free article.

8

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Harding JJ, El Dika I, Abou-Alfa GK. Harding JJ, et al. Cancer. 2016 Feb 1;122(3):367-77. doi: 10.1002/cncr.29769. Epub 2015 Nov 5. Cancer. 2016. PMID: 26540029 Free article. Review.

9

Acute myeloid leukemia masquerading as hepatocellular carcinoma.

Abu-Zeinah GF, Weisman P, Ganesh K, Katz SS, Dogan A, Abou-Alfa GK, Stein EM, Jarnagin W, Mauro MJ, Harding JJ. Abu-Zeinah GF, et al. J Gastrointest Oncol. 2016 Jun;7(3):E31-5. doi: 10.21037/jgo.2015.12.01. J Gastrointest Oncol. 2016. PMID: 27284485 Free PMC article.

10

Advanced Hepatocellular Cancer: the Current State of Future Research.

Connell LC, Harding JJ, Abou-Alfa GK. Connell LC, et al. Curr Treat Options Oncol. 2016 Aug;17(8):43. doi: 10.1007/s11864-016-0415-3. Curr Treat Options Oncol. 2016. PMID: 27344158 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page